Related Experiment Video
Updated: Feb 5, 2026

Author Spotlight: Extended Oxygen Consumption Measurement in Retinal Pigment Epithelium Using Resipher
Published on: August 16, 2024
Long-term prospective mood self-rating and antidepressant treatment
Sumana Gadde1, Carl Brown1, Amy Shah1
1Mood Disorders Research Programme,Department of Psychiatry,University of Louisville School of Medicine,Louisville,Kentucky,USA.
Abstract:
The use of antidepressants in bipolar illness remains controversial. This controversy continues to be fuelled by short-term studies that inconsistently report efficacy or no benefit. However, long-term studies have been consistently unfavourable, suggesting that understanding the long-term course of the illness in the setting of antidepressant treatment is important. This is an extraordinary case in which prospectively collected daily mood ratings were available in a type I bipolar individual who had experienced minimal medication changes over a 21-year period was reviewed. Data regarding the number of euthymic days in the setting of antidepressant use and after antidepressant discontinuation were collected. Induction of cycling and increase in the number of depressed days occurred after five years of continuous serotonergic antidepressant administration. Discontinuation of antidepressants after 11 years of continuous use was associated with only a partial improvement which had a delayed onset. Cycling and increase in depression was noted after years of continuous use of serotonergic antidepressant treatment. Antidepressant-associated destabilisation may occur after long-term exposure and may be associated with prolonged worsening even after antidepressant discontinuation.
Related Concept Videos
Antidepressant Drugs: Overview
Traits, Mood, and Subjective Wellbeing
Neuroticism and...
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Antidepressant Drugs: MAOIs and Other Agents
Long-term Depression
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

